Location:Home > News > Industry news
FDA Approves Merck’s LIPTRUZET? (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol
Author:admin  Source:  AddDate:2014-07-28

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved LIPTRUZET?(ezetimibe and atorvastatin) tablets for the treatment of elevated low density lipoprotein (LDL) cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough. LIPTRUZET (pronounced LIP true zett) contains ezetimibe, an efficacious LDL cholesterol lowering therapy, and atorvastatin, currently one of the most widely prescribed statins in the U.S.Once daily LIPTRUZET treats  two sources of cholesterol by inhibiting both the absorption of cholesterol in the digestive tract – through ezetimibe – and the production of cholesterol in the liver   through atorvastatin.

No incremental benefit of LIPTRUZET on cardiovascular morbidity and mortality over and above that demonstrated for atorvastatin has been established.

Previous:Forest to Present Aclidinium...
Next:Sensipar (Cinacalcet...